Health Economics›Acute promyelocytic leukemia›Consolidation after upfront therapy

Consolidation after upfront therapy

Acute promyelocytic leukemia · 12 regimens

Cost estimates only — modelled on a typical patient (BSA 1.7 m², 70 kg, CrCl 90 mL/min) using the cheapest available formulary presentation. Excludes vial wastage, facility fees, supportive care, and infusion consumables. Not for billing, formulary decisions, or clinical use.

Filters

Y-axis

Cost vs Efficacy

No data points — cost or PFS missing for current selection.

Regimen	Biomarker	Cost/cycle ↓	Cycle	PFS ↕	OS ↕	Est. cycles	Course cost ↕	Evidence
Arsenic trioxide and ATRA Variant #05	—	R 401 122	—	—	—	~1	~R 401 122 PFS proxy · indirect	1
Arsenic trioxide-ATRA and Daunorubicin Variant #01	—	R 111 208	49d	—	—	~2	~R 124 677 indirect	—
Cytarabine and Idarubicin, then Etoposide and Mitoxantrone, then Cytarabine, Idarubicin, Thioguanine, with ATRA Variant #01	—	R 55 107	—	—	—	~3	~R 70 589 indirect	—
Cytarabine and Idarubicin, then Etoposide and Mitoxantrone, then Cytarabine, Idarubicin, Thioguanine N/A - protocol	—	R 49 799	—	—	—	~3	~R 149 396 indirect	—
Cytarabine and Idarubicin, then Mitoxantrone, then Cytarabine and Idarubicin, with ATRA Variant #01	—	R 46 394	30d	—	—	~3	~R 61 877 indirect	—
Idarubicin, then Mitoxantrone, then Idarubicin, with ATRA Variant #01	—	R 44 061	30d	—	—	~3	~R 81 569 indirect	—
Arsenic trioxide monotherapy Variant #01	—	R 39 096	60d	—	—	~6	~R 234 574 indirect	—
Idarubicin, then Mitoxantrone, then Idarubicin Variant #01	—	R 33 928	30d	—	—	~1	~R 33 928 indirect	—
Cytarabine and Daunorubicin Variant #01	—	R 18 067	30d	—	—	~2	~R 24 307 indirect	—
ATRA and Daunorubicin Variant #01	—	R 13 469	90d	—	—	~2	~R 26 938 indirect	—
Cytarabine and Idarubicin Variant #01	—	R 12 853	30d	—	—	~1	~R 12 853 indirect	—
Daunorubicin monotherapy Variant #01	—	R 12 849	—	—	—	~1	~R 12 849 indirect	—

12 of 12 regimens shown